Zhaofei Liu, PhD

Boya Distinguished Professor

Department of Radiation Medicine;

School of Basic Medical Sciences,

Peking University, Beijing 100191, China

Contact Information

Office: Room 516, Central Laboratory Building; Tel: +86-10-82805825; Email: liuzf@bjmu.edu.cn

Research Interests

1. Molecular image-guided precision immunotherapy and radiotherapy for cancer

2. Development of novel radiopharmaceuticals to overcome clinical bottlenecks in nuclear medicine

Biography

Dr. Liu received his M.D. degree from Qingdao University Medical College in 2004 and his Ph.D. in Radiation Medicine from Peking University in 2009. During his doctoral studies, he conducted joint training at the Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine. After completing his Ph.D., he joined Peking University, where he has served as Lecturer (2009), Associate Professor (2011), and Professor (2016). Dr. Liu’s research focuses on molecular imaging and targeted radiotheranostics in oncology. He has authored more than 50 peer-reviewed papers in leading journals, including J Clin Invest, PNAS, Cancer Res, Nat Commun, and J Nucl Med.

Representative Publications

1. Liu N, Yang X, Gao C, Wang J, Zeng Y, Zhang L, Yin Q, Zhang T, Zhou H, Li K, Du J, Zhou S, Zhao X, Zhu H, Yang Z, Liu Z*. Noninvasively deciphering the immunosuppressive tumor microenvironment using galectin-1 PET to inform immunotherapy responses. J Nucl Med. 2024, 65:728-34.

2. Gao C, Zeng Y, Zhang L, Wang J, Yang X, Li K, Ren H*, Liu Z*. Sustained secretion of CCL21 via an implantable cell-reservoir hydrogel enhances the systemic antitumor effect of radiotherapy. Nano Lett. 2024, 24:5894-903.

3. Zhou H, Wang Y, Xu H, Shen X, Zhang T, Zhou X, Zeng Y, Li K, Zhang L, Zhu H, Yang X*, Li N*, Yang Z, Liu Z*. Noninvasive interrogation of CD8⁺ T cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest. 2022, 132:e161065.

4. Lu D, Zhou H, Li N, Wang Y, Zhang T, Wang F, Liu N, Zhu H, Zhang J, Yang Z, Liu Z*. Galectin expression detected by ⁶⁸Ga-galectracer PET as a predictive biomarker of radiotherapy resistance. Eur J Nucl Med Mol Imaging. 2022, 49:2746-60.

5. Zhao Y, Zhang T, Wang Y, Lu D, Du J, Feng X, Zhou H, Liu N, Zhu H, Qin S, Liu C, Gao X, Yang Z, Liu Z*. ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. Proc Natl Acad Sci U S A. 2021, 118:e2010333118.

6. Feng X, Wang Y, Lu D, Xu X, Zhou X, Zhang H, Zhang T, Zhu H, Yang Z, Wang F, Li N*, Liu Z*. Clinical translation of a ⁶⁸Ga-labeled integrin αvβ6-targeting cyclic radiotracer for PET imaging of pancreatic cancer. J Nucl Med. 2020, 61:1461-7.

7. Wang Y, Zhang C, Lai J, Zhao Y, Lu D, Bao R, Feng X, Zhang T, Liu Z*. Noninvasive PET tracking of post-transplant gut microbiota in living mice. Eur J Nucl Med Mol Imaging. 2020, 47:991-1002.

8. Zhao Y, Zhang C, Gao L, Yu X, Lai J, Lu D, Bao R, Wang Y, Jia B, Wang F, Liu Z*. Chemotherapy-induced macrophage infiltration into tumors enhances nanographene-based phtodynamic therapy. Cancer Res. 2017, 77:6021-32.

9. Yu X, Gao D, Gao L, Lai J, Zhang C, Zhao Y, Zhong L, Jia B, Wang F, Chen X, Liu Z*. Inhibiting metastasis and preventing tumor relapse by triggering host immunity with tumor-targeted photodynamic therapy using photosensitizer-loaded functional nanographenes. ACS Nano. 2017, 11:10147-58.

10. Gao L, Liu H, Sun X, Gao D, Zhang C, Jia B, Zhu Z, Wang F, Liu Z*. Molecular imaging of post-Src-inhibition tumor signatures for guiding dasatinib combination therapy. J Nucl Med. 2016, 57:321-6.